Metalloproteinase inhibition augments antitumor efficacy of the anti-CD30 immunotoxin Ki-3(scFv)-eta′ against human lymphomas in vivo

International Journal of Cancer

Volumn 111, Issue 4, 2004, Pages 568-574

  Matthey, Baerbel ^a   Borchmann, Peter ^a   Schnell, Roland ^a   Tawadros, Samir ^a   Lange, Hans ^b   Huhn, Michael ^c   Klimka, Alexander ^c   Tur, Mehmet K ^c   Barth, Stefan ^c   Engert, Andreas ^a   Hansen, Hinrich P ^a,d  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY OF KIEL   (Germany)

^c FRAUNHOFER INSTITUTE FOR MOLECULAR BIOLOGY AND APPLIED ECOLOGY IME   (Germany)

^d UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

CD30; Ectodomain shedding; Hydroxamate inhibitor; Immunotherapy; Recombinant immunotoxins

Indexed keywords

CD30 ANTIGEN; IMMUNOTOXIN; KI 3 SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY DELETION MUTANT OF PSEUDOMONAS EXOTOXIN A; METALLOPROTEINASE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD30; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; SOLIMASTAT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; DELETION MUTANT; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG EFFICACY; ENZYME INHIBITION; GENE OVEREXPRESSION; HODGKIN DISEASE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LYMPHOMA; LYMPHOMA CELL; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PUMP; SCID MOUSE; SURVIVAL TIME; TARGET CELL; TUMOR GROWTH;

AMINOPYRIDINES; ANIMALS; ANTIBODIES; ANTIGENS, CD30; HODGKIN DISEASE; HYDROXAMIC ACIDS; IMMUNOTHERAPY; IMMUNOTOXINS; METALLOENDOPEPTIDASES; MICE; MICE, SCID; SURVIVAL ANALYSIS; TUMOR CELLS, CULTURED;

EID: 3843059318     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.20278     Document Type: Article

References (30)

1. Kanzler H, Hansmann ML, Kapp U, Wolf J, Diehl V, Rajewsky K, Kuppers R. Molecular single cell analysis demonstrates the derivation of a peripheral blood-derived cell line (L1236) from the Hodgkin/ Reed-Sternberg cells of a Hodgkin's lymphoma patient. Blood 1996;87:3429-36.
2. Wolf J, Kapp U, Bohlen H, Kornacker M, Schoch C, Stahl B, Mucke S, von Kalle C, Fonatsch C, Schaefer HE, Hansmann ML, Diehl V. Peripheral blood mononuclear cells of a patient with advanced Hodgkin's lymphoma give rise to permanently growing Hodgkin-Reed Sternberg cells. Blood 1996;87:3418-28.
3. Agnarsson BA, Kadin ME. The immunophenotype of Reed-Sternberg cells: a study of 50 cases of Hodgkin's disease using fixed frozen tissues. Cancer 1989;63:2083-7.
4. Schwab U, Stein H, Gerdes J, Lemke H, Kirchner H, Schaadt M, Diehl V. Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin's disease and a subset of normal lymphoid cells. Nature 1982;299:65-7.
5. Froese P, Lemke H, Gerdes J, Havsteen B, Schwarting R, Hansen H, Stein H. Biochemical characterization and biosynthesis of the Ki-1 antigen in Hodgkin-derived and virus-transformed human B and T lymphoid cell lines. J Immunol 1987;139:2081-7.
6. Durkop H, Latza U, Hummel M, Eitelbach F, Seed B, Stein H. Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease. Cell 1992;68:421-7.
7. Horie R, Watanabe T. CD30: expression and function in health and disease. Semin Immunol 1998;10:457-70.
8. Engert A, Burrows F, Jung W, Tazzari PL, Stein H, Pfreundschuh M, Diehl V, Thorpe P. Evaluation of ricin A chain-containing immunotoxins directed against the CD30 antigen as potential reagents for the treatment of Hodgkin's disease. Cancer Res 1990;50:84-8.
9. Schnell R, Linnartz C, Katouzi AA, Schon G, Bohlen H, Horn-Lohrens O, Parwaresch RM, Lange H, Diehl V, Lemke H, Engert A. Development of new ricin A-chain immunotoxins with potent antitumor effects against human Hodgkin cells in vitro and disseminated Hodgkin tumors in SCID mice using high-affinity monoclonal antibodies directed against the CD30 antigen. Int J Cancer 1995;63:238-44.
10. Klimka A, Barth S, Matthey B, Roovers RC, Lemke H, Hansen H, Arends JW, Diehl V, Hoogenboom HR, Engert A. An anti-CD30 single-chain Fv selected by phage display and fused to Pseudomonas exotoxin A (Ki-4(scFv)-ETA′) is a potent immunotoxin against a Hodgkin-derived cell line. Br J Cancer 1999;80:1214-22.
11. Barth S, Huhn M, Matthey B, Tawadros S, Schnell R, Schinkothe T, Diehl V, Engert A. Ki-4(scFv)-ETA′, a new recombinant anti-CD30 immunotoxin with highly specific cytotoxic activity against disseminated Hodgkin tumors in SCID mice. Blood 2000;95:3909-14.
12. Falini B, Bolognesi A, Flenghi L, Tazzari PL, Broe MK, Stein H, Durkop H, Aversa F, Corneli P, Pizzolo G, Barbabietola G, Sabattini E. Response of refractory Hodgkin's disease to monoclonal anti-CD30 immunotoxin. Lancet 1992;339:1195-6.
13. Pasqualucci L, Flenghi L, Terenzi A, Bolognesi A, Stirpe F, Bigerna B, Falini B. Immunotoxin therapy of hematological malignancies. Haematologica 1995;80:546-56.
14. Schnell R, Borchmann P, Schulz H, Engert A. Current strategies of antibody-based treatment in Hodgkin's disease. Ann Oncol 2002;13(Suppl 1):57-66.
15. Hansen HP, Dietrich S, Kisseleva T, Mokros T, Mentlein R, Lange HH, Murphy G, Lemke H. CD30 shedding from Karpas 299 lymphoma cells is mediated by TNF-alpha-converting enzyme. J Immunol 2000;165:6703-9.
16. Dello SP, Rovida E. Transmodulation of cell surface regulatory molecules via ectodomain shedding. Biol Chem 2002;383:69-83.
17. Hansen HP, Matthey B, Barth S, Kisseleva T, Mokros T, Davies SJ, Beckett RP, Foelster-Holst R, Lange HH, Engert A, Lemke H. Inhibition of metalloproteinases enhances the internalization of anti-CD30 antibody Ki-3 and the cytotoxic activity of Ki-3 immunotoxin. Int J Cancer 2002;98:210-5.
18. Lange H, Solterbeck M, Berek C, Lemke H. Correlation between immune maturation and idiotypic network recognition. Eur J Immunol 1996;26:2234-42.
19. McCafferty J, Fitzgerald KJ, Earnshaw J, Chiswell DJ, Link J, Smith R, Kenten J. Selection and rapid purification of murine antibody fragments that bind a transition-state analog by phage display. Appl Biochem Biotechnol 1994;47:157-71.
20. Grass HJ, Ulrich D, Braddy S, Armitage RJ, Dower SK. Recombinant CD30 ligand and CD40 ligand share common biological activities on Hodgkin and Reed-Sternberg cells. Eur J Immunol 1995;25:2083-9.
21. Horn-Lohrens O, Tiemann M, Lange H, Kobarg J, Hafner M, Hansen H, Sterry W, Parwaresch RM, Lemke H. Shedding of the soluble form of CD30 from the Hodgkin-analogous cell line L540 is strongly inhibited by a new CD30-specific antibody (Ki-4). Int J Cancer 1995;60:539-44.
22. Rohde D, Hansen H, Hafner M, Lange H, Mielke V, Hansmann ML, Lemke H. Cellular localizations and processing of the two molecular forms of the Hodgkin-associated Ki-1 (CD30) antigen: the protein kinase Ki-1/57 occurs in the nucleus. Am J Pathol 1992;140:473-82.
23. + Hodgkin's and non-Hodgkin's lymphoma. Clin Cancer Res 2002;8:1779-86.
24. Brown PD. Clinical studies with matrix metalloproteinase inhibitors. Apmis 1999;107:174-80.
25. Drummond AH, Beckett P, Brown PD, Bone EA, Davidson AH, Galloway WA, Gearing AJ, Huxley P, Laber D, McCourt M, Whittaker M, Wood LM, et al. Preclinical and clinical studies of MMP inhibitors in cancer. Ann NY Acad Sci 1999;878:228-35.
26. Wojtowicz-Praga S, Torri J, Johnson M, Steen V, Marshall J, Ness E, Dickson R, Sale M, Rasmussen HS, Chiodo TA, Hawkins MJ. Phase 1 trial of Marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer. J Clin Oncol 1998;16:2150-6.
27. Hidalgo M, Eckhardt SG. Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl Cancer Inst 2001;93:178-93.
28. Dong L, Hulsmeyer M, Durkop H, Hansen HP, Schneider-Mergener J, Ziegler A, Uchanska-Ziegler B. Human CD30: structural implications from epitope mapping and modeling studies. J Mol Recognit 2003;16:28-36.
29. Molina MA, Codony-Servat J, Albanell J, Rojo F, Arribas J, Baselga J. Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res 2001;61:4744-9.
30. Codony-Servat J, Albanell J, Lopez-Talavera JC, Arribas J, Baselga J. Cleavage of the HER2 ectodomain is a pervanadate-activable process that is inhibited by the tissue inhibitor of metalloproteases-1 in breast cancer cells. Cancer Res 1999;59:1196-201.